SCHEDULE: Nano Dimension Ltd. Schedule 13D Filing Update

Oramed Pharmaceuticals Inc. reports changes in beneficial ownership of Nano Dimension Ltd. ordinary shares, including option and put option transactions.

Summary

• Oramed Pharmaceuticals Inc. (the Reporting Person) has filed an amendment to its Schedule 13D concerning Nano Dimension Ltd. ordinary shares.
• On July 20, 2026, the Reporting Person purchased call options referencing 8,200,000 ordinary shares for approximately $1,258,000.
• The same day, the Reporting Person sold 8,200,000 ordinary shares at $1.55 per share.
• The Reporting Person also engaged in other option transactions, including purchasing call options and selling put options with various strike prices and expiration dates.
• Following these transactions, the Reporting Person no longer beneficially owns more than five percent of Nano Dimension Ltd.'s outstanding ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting on transactional changes in beneficial ownership and derivative positions without significant strategic revelations or performance indicators.

Positives

• The Reporting Person has actively managed its position in Nano Dimension Ltd. through strategic option and share transactions.
• The company utilized general working capital for its transactions, indicating no immediate need for external financing for these specific trades.

Negatives

• The Reporting Person has ceased to beneficially own more than five percent of the outstanding ordinary shares, potentially reducing its influence or stake.
• Significant trading activity on a single day suggests a dynamic and potentially volatile strategy regarding the investment.

Risks

• The value of the purchased call options is subject to market fluctuations and the performance of Nano Dimension Ltd.'s stock.
• The sale of put options carries the risk of being obligated to purchase shares if the stock price falls below the strike price.
• The overall strategy involving complex option trades introduces inherent risks associated with derivatives.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from Nano Dimension Ltd. The transactions described are historical events.

Management Comments

• Funds used for the purchase of securities were derived from the general working capital of the Reporting Person.
• The Reporting Person is no longer a party to any options contracts with respect to the Ordinary Shares following the reported transactions.

Industry Context

StockSavvy.ai notes that this filing reflects active portfolio management by Oramed Pharmaceuticals Inc. within the biotechnology or advanced materials sector, characterized by significant trading in equity derivatives to adjust positions.

Stakeholder Impact

• Shareholders of Nano Dimension Ltd. may see a change in the significant beneficial ownership landscape, potentially impacting market dynamics.
• Investors in Oramed Pharmaceuticals Inc. will note the active management of its investment portfolio through derivative and equity transactions.

Next Steps

• The Reporting Person has ceased to beneficially own more than five percent of the outstanding Ordinary Shares.
• The Reporting Person is no longer a party to any options contracts with respect to the Ordinary Shares.

Key Dates

Keywords

Schedule 13D, Nano Dimension Ltd., Oramed Pharmaceuticals Inc., Ordinary Shares, Call Options, Put Options, Beneficial Ownership, Securities Transactions